333 related articles for article (PubMed ID: 21881697)
1. ARBs for cardiovascular and renal protection in high-risk patients.
Aalbers J
Cardiovasc J Afr; 2011; 22(4):224. PubMed ID: 21881697
[No Abstract] [Full Text] [Related]
2. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
Oparil S; Kjeldsen SE; Hedner T; Narkiewicz K
Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085
[No Abstract] [Full Text] [Related]
3. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
Serebruany VL; Atar D; Hanley DF
Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
[No Abstract] [Full Text] [Related]
4. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
[TBL] [Abstract][Full Text] [Related]
5. [New studies on hypertension of great significance to clinical practice. Also very old persons benefit from blood pressure reduction].
Nilsson PM
Lakartidningen; 2008 May 7-13; 105(19):1382-4. PubMed ID: 18574975
[No Abstract] [Full Text] [Related]
6. [Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection].
MMW Fortschr Med; 2007 Dec; 149(49-50):52-3. PubMed ID: 18236984
[No Abstract] [Full Text] [Related]
7. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
Middeke M
Dtsch Med Wochenschr; 2012 Nov; 137(48):2498. PubMed ID: 23168983
[No Abstract] [Full Text] [Related]
8. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381
[No Abstract] [Full Text] [Related]
9. ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure.
Cardiovasc J Afr; 2008; 19(2):108-9; discussion 109-10. PubMed ID: 18516357
[No Abstract] [Full Text] [Related]
10. [Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].
Burnier M; Waeber B; Hess O; Lüscher T
Praxis (Bern 1994); 2008 May; 97(10):559-62. PubMed ID: 18595371
[No Abstract] [Full Text] [Related]
11. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
Sharma A; Baliga V;
J Indian Med Assoc; 2008 Mar; 106(3):191-4, 196. PubMed ID: 18712142
[TBL] [Abstract][Full Text] [Related]
12. Is therapy of people with chronic kidney disease ONTARGET?
Mann JF; Tobe S; Teo KK; Yusuf S
Nephrol Dial Transplant; 2010 Jan; 25(1):42-4. PubMed ID: 19854846
[No Abstract] [Full Text] [Related]
13. [The ONTARGET trial].
Verdecchia P; Terrosu P
G Ital Cardiol (Rome); 2009 Feb; 10(2):67-72. PubMed ID: 19348142
[No Abstract] [Full Text] [Related]
14. Telmisartan in high-risk cardiovascular patients.
Weber MA
Am J Cardiol; 2010 Jan; 105(1 Suppl):36A-43A. PubMed ID: 20102972
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
Baumhäkel M; Böhm M
Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
[TBL] [Abstract][Full Text] [Related]
16. Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?
Neldam S
Future Cardiol; 2010 Jan; 6(1):129-35. PubMed ID: 20014992
[TBL] [Abstract][Full Text] [Related]
17. Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.
Mancia G; Unger T; Zanchetti A
J Hypertens Suppl; 2009 Jul; 27(5):S1. PubMed ID: 19587549
[No Abstract] [Full Text] [Related]
18. Renin-angiotensin system blockade and cardiovascular and renal protection.
Hoogwerf BJ
Am J Cardiol; 2010 Jan; 105(1 Suppl):30A-5A. PubMed ID: 20102971
[TBL] [Abstract][Full Text] [Related]
19. New data on ONTARGET: more confusion?
Escobar C; Echarri R; Barrios V
J Clin Hypertens (Greenwich); 2010 Mar; 12(3):199. PubMed ID: 20433538
[No Abstract] [Full Text] [Related]
20. ONTARGET should not be over interpreted.
Abutaleb N
Nephrol Dial Transplant; 2010 Jan; 25(1):44-7. PubMed ID: 19934088
[No Abstract] [Full Text] [Related]
[Next] [New Search]
